Abstract:Significance Identification of cancer cells in the pleural effusions of lung cancer patients is an important clinical diagnosis to verify the malignant pleural involvement. Elevated glucose uptake is a hallmark of cancer cells and has been used in positron-emission tomography to detect malignant tumors in vivo. We hypothesize that cells with enhanced glucose uptake and without expression of leukocyte markers in pleural effusion or peripheral blood samples are highly likely to be malignant cells that can be confirmed via single-cell sequencing. To this end, a high-throughput metabolic-based assay is developed for rapid detection of rare metabolically active tumor cells in pleural effusion, enabling sensitive diagnosis of malignant pleural effusion in the clinic that is associated with metastatic malignancies. Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies. Accurate detection of tumor cells in pleural fluid is crucial because the presence of MPE denotes an advanced stage of disease and directs a switch in clinical managements. Cytology, as a traditional diagnostic tool, has limited sensitivity especially when tumor cells are not abundant, and may be confounded by reactive mesothelial cells in the pleural fluid. We describe a highly sensitive approach for rapid detection of metabolically active tumor cells in MPE via exploiting the altered glucose metabolism of tumor cells relative to benign cells. Metabolically active tumor cells with high glucose uptake, as evaluated by a fluorescent glucose analog (2-NBDG), are identified by high-throughput fluorescence screening within a chip containing 200,000 addressable microwells and collected for malignancy confirmation via single-cell sequencing. We demonstrate the utility of this approach through analyzing MPE from a cohort of lung cancer patients. Most candidate tumor cells identified are confirmed to harbor the same driver oncogenes as their primary lesions. In some patients, emergence of secondary mutations that mediate acquired resistance to ongoing targeted therapies is also detected before resistance is manifested in the clinical imaging. The detection scheme can be extended to analyze peripheral blood samples. Our approach may serve as a valuable complement to cytology in MPE diagnosis, helping identify the driver oncogenes and resistance-leading mutations for targeted therapies.

Assessment of Drug Susceptibility for Patient-Derived Tumor Models through Lactate Biosensing and Machine Learning

A Novel Micro-Groove Impedance Sensor for 3D Cell Viability Monitoring and High-Throughput Drug Screening

3D Microgroove Electrical Impedance Sensing to Examine 3D Cell Cultures for Antineoplastic Drug Assessment

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

In vitro and in vivo detection of lactate with nanohybrid-functionalized Pt microelectrode facilitating assessment of tumor development

Prognostic implication of a novel lactate score correlating with immunotherapeutic responses in pan-cancer

Multiplexed Single-Cell Measurements of FDG Uptake and Lactate Release Using Droplet Microfluidics

Establishment and Verification of a Novel Gene Signature Connecting Hypoxia and Lactylation for Predicting Prognosis and Immunotherapy of Pancreatic Ductal Adenocarcinoma Patients by Integrating Multi-Machine Learning and Single-Cell Analysis

Unravelling the metabolic landscape of cutaneous melanoma: Insights from single‐cell sequencing analysis and machine learning for prognostic assessment of lactate metabolism

Surface Immobilization of Redox‐Labile Fluorescent Probes: Enabling Single‐Cell Co‐Profiling of Aerobic Glycolysis and Oncogenic Protein Signaling Activities

A Novel Risk Score Model of Lactate Metabolism for Predicting over Survival and Immune Signature in Lung Adenocarcinoma

Epco-36. Integrative Deep-Learning And Pharmacogenomic Profiling Of Malignant Gliomas Using Patient-Derived Tumor Cells

Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication

Characterization of a Lactate Metabolism-Related Signature for Evaluation of Immune Features and Prediction Prognosis in Glioma.

Prediction of Cancer Patient Responses to Different Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles.

Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics

A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses

High-throughput Screening of Rare Metabolically Active Tumor Cells in Pleural Effusion and Peripheral Blood of Lung Cancer Patients

Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma

Integrative Dissection of Novel Lactate Metabolism-Related Signature in the Tumor Immune Microenvironment and Prognostic Prediction in Breast Cancer